FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312643485> ?p ?o ?g. }

• W4312643485 endingPage "41" @default.
• W4312643485 startingPage "34" @default.
• W4312643485 abstract "Biosimilars follow a rigorous regulatory approval pathway designed to collect and review the totality of evidence from non-clinical analytical comparability exercises as well as clinical Phase I and III studies between the biosimilar and the reference biological. Once the European Medicines Agency (EMA) has given a positive opinion on the generated totality of evidence, the agency may extrapolate the biosimilar’s clinical data from the indication in which the biosimilar was studied to other indications for which the reference biological was approved. A prerequisite for this step is a convincing demonstration of biosimilarity within a studied clinical Phase III population that is suitably sensitive to detect potential clinically relevant differences in efficacy, safety, or immunogenicity. This regulatory pathway was used for all currently available biosimilars including SB2 (Flixabi®), a recently approved biosimilar that is licensed for use across all indications approved for its reference biologic infliximab (Remicade®), including inflammatory bowel disease (IBD). Further to robust non-clinical evaluations of SB2 in 46 physicochemical and 23 biological assays, a Phase I study demonstrated pharmacokinetic equivalence between SB2 and reference infliximab. Furthermore, a Phase III study performed in patients with moderate-to-severe rheumatoid arthritis (RA) — a scientifically appropriate, sensitive patient population — showed that SB2 was equivalent to infliximab in terms of its primary endpoint, American College of Rheumatology 20% improvement (ACR20) response rate at Week 30, and comparable with regard to safety and immunogenicity up to Week 54. Additional analyses of treatment-emergent adverse events (TEAEs) by anti-drug antibody (ADA) status up to Week 54 demonstrated a comparable incidence of TEAEs in both treatment arms. The ACR response rates, safety, and incidence of ADAs remained comparable also in the transition extension period up to Week 78 between patients who continued to receive either SB2 or reference infliximab, and patients who transitioned from reference infliximab to SB2. Biosimilars have an important place in the treatment of IBD. Increased use of biosimilars in patients with Crohn’s disease (CD) or ulcerative colitis is likely to reduce costs, expand access of eligible patients to biologic therapy, and improve overall health outcomes." @default.
• W4312643485 created "2023-01-05" @default.
• W4312643485 creator A5079535209 @default.
• W4312643485 date "2016-12-01" @default.
• W4312643485 modified "2023-10-16" @default.
• W4312643485 title "Introducing Biosimilars into Current Inflammatory Bowel Disease Treatment Algorithms" @default.
• W4312643485 cites W1850535375 @default.
• W4312643485 cites W1942766989 @default.
• W4312643485 cites W2010007856 @default.
• W4312643485 cites W2023193839 @default.
• W4312643485 cites W2024155192 @default.
• W4312643485 cites W2049827204 @default.
• W4312643485 cites W2088158803 @default.
• W4312643485 cites W2105802338 @default.
• W4312643485 cites W2108079348 @default.
• W4312643485 cites W2129372955 @default.
• W4312643485 cites W2160745171 @default.
• W4312643485 cites W2174460595 @default.
• W4312643485 cites W2259088801 @default.
• W4312643485 cites W2290587826 @default.
• W4312643485 cites W2314763045 @default.
• W4312643485 cites W2554687389 @default.
• W4312643485 cites W2808141733 @default.
• W4312643485 cites W4255263503 @default.
• W4312643485 doi "https://doi.org/10.33590/emjgastroenterol/10312373" @default.
• W4312643485 hasPublicationYear "2016" @default.
• W4312643485 type Work @default.
• W4312643485 citedByCount "0" @default.
• W4312643485 crossrefType "journal-article" @default.
• W4312643485 hasAuthorship W4312643485A5079535209 @default.
• W4312643485 hasBestOaLocation W43126434851 @default.
• W4312643485 hasConcept C126322002 @default.
• W4312643485 hasConcept C177713679 @default.
• W4312643485 hasConcept C197934379 @default.
• W4312643485 hasConcept C2777138892 @default.
• W4312643485 hasConcept C2777575956 @default.
• W4312643485 hasConcept C2778260677 @default.
• W4312643485 hasConcept C2778715236 @default.
• W4312643485 hasConcept C2779134260 @default.
• W4312643485 hasConcept C2908647359 @default.
• W4312643485 hasConcept C535046627 @default.
• W4312643485 hasConcept C59491497 @default.
• W4312643485 hasConcept C71924100 @default.
• W4312643485 hasConcept C98274493 @default.
• W4312643485 hasConcept C99454951 @default.
• W4312643485 hasConceptScore W4312643485C126322002 @default.
• W4312643485 hasConceptScore W4312643485C177713679 @default.
• W4312643485 hasConceptScore W4312643485C197934379 @default.
• W4312643485 hasConceptScore W4312643485C2777138892 @default.
• W4312643485 hasConceptScore W4312643485C2777575956 @default.
• W4312643485 hasConceptScore W4312643485C2778260677 @default.
• W4312643485 hasConceptScore W4312643485C2778715236 @default.
• W4312643485 hasConceptScore W4312643485C2779134260 @default.
• W4312643485 hasConceptScore W4312643485C2908647359 @default.
• W4312643485 hasConceptScore W4312643485C535046627 @default.
• W4312643485 hasConceptScore W4312643485C59491497 @default.
• W4312643485 hasConceptScore W4312643485C71924100 @default.
• W4312643485 hasConceptScore W4312643485C98274493 @default.
• W4312643485 hasConceptScore W4312643485C99454951 @default.
• W4312643485 hasLocation W43126434851 @default.
• W4312643485 hasOpenAccess W4312643485 @default.
• W4312643485 hasPrimaryLocation W43126434851 @default.
• W4312643485 hasRelatedWork W2064858719 @default.
• W4312643485 hasRelatedWork W2109176553 @default.
• W4312643485 hasRelatedWork W2279977120 @default.
• W4312643485 hasRelatedWork W2341953096 @default.
• W4312643485 hasRelatedWork W2786419811 @default.
• W4312643485 hasRelatedWork W2956005210 @default.
• W4312643485 hasRelatedWork W3162050615 @default.
• W4312643485 hasRelatedWork W4206985838 @default.
• W4312643485 hasRelatedWork W4253917565 @default.
• W4312643485 hasRelatedWork W4293162410 @default.
• W4312643485 isParatext "false" @default.
• W4312643485 isRetracted "false" @default.
• W4312643485 workType "article" @default.